Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.45|
|52 Week High||US$1.20|
|52 Week Low||US$2.36|
|1 Month Change||10.69%|
|3 Month Change||-2.69%|
|1 Year Change||-13.69%|
|3 Year Change||-37.23%|
|5 Year Change||-34.09%|
|Change since IPO||-81.29%|
Recent News & Updates
Geron: Potential For Mind-Bending Returns With Current Pipeline
Geron's main product pipeline is a therapeutic in the cancer treatment market which showed promise but not great potential. Given expectations for the product, if approved, relative to current market sentiment, I believe mind-bending returns of over 1,000% are possible and worth the risk of a small position. I am initiating a small position and have a bullish stance on the company's 5-year prospects.
Geron surges after publication of IMbark Phase 2 data
Geron (GERN) +19.8% post-market after reporting the publication of data supporting the ongoing IMbark Phase 2 clinical trial in the Journal of Clinical Oncology.Geron says the publication "highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as the evidence of disease-modifying activity from biomarker and bone marrow fibrosis assessments."The company is evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis, a rare type of blood cancer.Geron says data from the Phase 2 clinical trials
|GERN||US Biotechs||US Market|
Return vs Industry: GERN underperformed the US Biotechs industry which returned 28.4% over the past year.
Return vs Market: GERN underperformed the US Market which returned 36.2% over the past year.
Stable Share Price: GERN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: GERN's weekly volatility (7%) has been stable over the past year.
About the Company
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Fundamentals Summary
|GERN fundamental statistics|
Is GERN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GERN income statement (TTM)|
|Cost of Revenue||US$71.46m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.31|
|Net Profit Margin||-25,083.58%|
How did GERN perform over the long term?See historical performance and comparison
Is Geron undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GERN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GERN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GERN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: GERN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GERN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GERN is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (3.2x).
How is Geron forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GERN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GERN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GERN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GERN's revenue (83.9% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: GERN's revenue (83.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GERN's Return on Equity is forecast to be high in 3 years time
How has Geron performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GERN is currently unprofitable.
Growing Profit Margin: GERN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GERN is unprofitable, and losses have increased over the past 5 years at a rate of 34.7% per year.
Accelerating Growth: Unable to compare GERN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GERN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: GERN has a negative Return on Equity (-57.23%), as it is currently unprofitable.
How is Geron's financial position?
Financial Position Analysis
Short Term Liabilities: GERN's short term assets ($201.8M) exceed its short term liabilities ($37.0M).
Long Term Liabilities: GERN's short term assets ($201.8M) exceed its long term liabilities ($39.0M).
Debt to Equity History and Analysis
Debt Level: GERN's debt to equity ratio (19.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GERN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GERN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GERN has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 33.9% each year.
What is Geron current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GERN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GERN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GERN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GERN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GERN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chip Scarlett (70 yo)
Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and its President since January 5, 2012. Dr. Scarlett is Chairman o...
CEO Compensation Analysis
Compensation vs Market: Chip's total compensation ($USD1.88M) is about average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Chip's compensation has been consistent with company performance over the past year.
Experienced Management: GERN's management team is seasoned and experienced (5.7 years average tenure).
Experienced Board: GERN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.
Geron Corporation's employee growth, exchange listings and data sources
- Name: Geron Corporation
- Ticker: GERN
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$455.251m
- Shares outstanding: 320.60m
- Website: https://www.geron.com
Number of Employees
- Geron Corporation
- 919 East Hillsdale Boulevard
- Suite 250
- Foster City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 22:55|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.